SCA acquires remaining 50% in Chilean hygiene company Papeles Industriales for 520M Swedish kroner, strengthens presence in Latin America; company becomes fully-owned subsidiary of SCA

STOCKHOLM , April 18, 2012 (press release) – SCA acquires the remaining 50 percent in the Chilean hygiene company PISA (Papeles Industriales S.A.), and will after the transaction own 100 percent of the company. The purchase price is approximately 520 MSEK.

The turnover 2011 was approximately 780 MSEK. The company is primarily operating within tissue for consumers and Away-From-Home usage, which represents almost 70 and almost 30 percent of the turnover, respectively. In addition, incontinence care products under SCA’s global brand TENA have been introduced in Chile through PISA.

SCA entered PISA with a 50 percent ownership during 2003. After the acquisition announced today, which is expected to be closed end of April, PISA will be a fully-owned subsidiary to SCA.

“The time is ready for us to take the next step in our expansion in Latin America, where the PISA acquisition further strengthens our presence on this important growth market,” says Jan Johansson, CEO and President of SCA.

PISA holds a position as number two in consumer tissue with the brand Favorita. Within AFH tissue, PISA also holds a number two position in Chile. The company has over 400 employees and a production facility in the capital Santiago.

SCA is a global hygiene and paper company that develops and produces personal care products, tissue, publication papers, solid-wood products and packaging solutions. Sales are conducted in some 100 countries. SCA has many well-known brands, including the global brands TENA and Tork. Sales in 2011 amounted to SEK 106 billion (EUR 11.7 billion). SCA has approximately 44,000 employees. More information at

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.